Patent ID: 7759333

Claim:
A method for treating AMD, DR, and/or retinal edema in a patient which comprises administering to the patient in need of such treatment a pharmaceutically effective amount of a compound of formula I: wherein: R 1-20 are independently H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, or heterocycloalkenyl, each of which is optionally substituted with an alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group; or two of the R groups on the same (e.g., R 1 and R 2 , or R 3 and R 4 , or R 5 and R 6 , etc.) or adjacent (e.g., R 1 and R 3 , or R 3 and R 5 , or R 6 and R 7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C 3-20 carbocycle, the carbocycle being optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group; or two of the R groups on the same (e.g., R 1 and R 2 , or R 3 and R 4 , or R 5 and R 6 , etc.) or adjacent (e.g., R 1 and R 3 , or R 3 and R 5 , or R 6 and R 7 , etc.) sites, together with the carbon atoms to which they are attached, form an optionally unsaturated or aromatic C 2-20 nitrogen-containing heterocycle, the heterocycle being optionally substituted optionally substituted with alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, heterocycloalkyl, heterocycloalkenyl, halo, trihalomethyl, acyl, alkoxycarbonyl, alkylsulfonyl, or arylsulfonyl group, or a free or functionally modified hydroxyl, amino, or thiol group; it being understood that in all cases the nitrogens binding the Mn center in the drawing for I will lack hydrogens when the nitrogen is already trisubstituted (e.g., when the relevant nitrogen is part of a pyridine ring); X, Y, and Z are pharmaceutically acceptable anions; and n is 0-3.